Publications by authors named "Suzanne Demko"

Claim this Profile
A
An open-label multi-center phase 1 safety study of BXQ-350 in children and young adults with relapsed solid tumors, including recurrent malignant brain tumors.
Mohamed S Abdelbaki, Mariko Dawn DeWire Schottmiller, Timothy P Cripe, Richard C Curry, Charles A Cruze, Suzanne Demko

Heliyon· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FDA Approval Summary: Selumetinib for Plexiform Neurofibroma.
Denise Casey, Suzanne Demko, Arup Sinha, Pallavi S Mishra-Kalyani, Yuan-Li Shen

Clin Cancer Res· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FDA Accelerated Approval of Pembrolizumab for Recurrent Locally Advanced or Metastatic Merkel Cell Carcinoma.
Diana Bradford, Suzanne Demko, Susan Jin, Pallavi Mishra-Kalyani, Aaliyah R Beckles

Oncologist· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FDA Approval Summary: Sonidegib-Response.
Stacy S Shord, Denise Casey, Hong Zhao, Suzanne Demko, Patricia Keegan

Clin Cancer Res· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FDA Approval Summary: Sonidegib for Locally Advanced Basal Cell Carcinoma.
Denise Casey, Suzanne Demko, Stacy Shord, Hong Zhao, Huanyu Chen

Clin Cancer Res· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
U.S. Food and Drug Administration Approval: peginterferon-alfa-2b for the adjuvant treatment of patients with melanoma.
Thomas M Herndon, Suzanne G Demko, Xiaoping Jiang, Kun He, Joseph E Gootenberg

Oncologist· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FDA drug approval summary: alemtuzumab as single-agent treatment for B-cell chronic lymphocytic leukemia.
Suzanne Demko, Jeffrey Summers, Patricia Keegan, Richard Pazdur

Oncologist· February 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis